PARIS--(BUSINESS WIRE)--Nov. 3, 2005--Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported that Dr. Bernard Escudier provided an update on the Nexavar(R) (sorafenib tosylate) Tablets Phase III trial in patients with advanced renal cell carcinoma (RCC), or kidney cancer during the thirteenth European Cancer Conference (ECCO). Dr. Escudier is the Head of Immunotherapy and Innovative Therapy Unit at the Gustave-Roussy Institute, Paris and co-principal investigator of the study along with Ronald Bukowski, M.D., Director of the Experimental Therapeutics Program of The Cleveland Clinic Taussig Cancer Center, Cleveland, OH.
